Gorlin Syndrome — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Gorlin syndrome, also known as Gorlin-Goltz syndrome, nevoid basal cell carcinoma syndrome (BCNS), or basal cell nevus syndrome, is an autosomal dominant familial cancer syndrome. It manifests with numerous basal cell carcinomas (BCCs) and is accompanied by skeletal, ophthalmologic, and neurologic abnormalities. The syndrome gives rise to multiple neoplasms that initiate during childhood. The underlying cause of basal cell nevus syndrome is mutations within the patched (PTCH) gene. This gene encodes a transmembrane receptor responsible for recognizing sonic hedgehog signaling proteins. The syndrome demonstrates a high degree of penetrance while expressing variability in its presentation. Around 20% to 30% of BCNS cases are due to de novo mutations. Individuals harboring one mutated copy of the PTCH1 gene in each cell can exhibit Gorlin syndrome features early in life, including skeletal irregularities and macrocephaly. For basal cell carcinomas and other tumors to emerge, a mutation must also affect the second copy of the PTCH1 gene in specific cells during the person’s lifetime. Individuals with one PTCH1 gene mutation will eventually acquire a second mutation in certain cells, ultimately developing diverse tumor types. Gorlin syndrome presents a range of symptoms and signals termed “indicators.” These include:
- Basal cell carcinomas (BCCs) are a form of skin cancer appearing on the face, hands, and back of the neck.
- Odontogenic keratocystic tumors (OKCs) benign cysts found in the jawbone.
- Small depressions or pits on the palms of the hands and the soles of the feet.
Currently, there exists no specific treatment or cure for Gorlin syndrome itself. Management of this syndrome focuses on preventing, handling, and removing tumors and cysts stemming from the condition. Various methods are available to eliminate the tumors and cysts associated with Gorlin syndrome, such as cryotherapy (freezing), laser treatments, and curettage (scraping).
- Gorlin syndrome is a rare genetic disorder that affects roughly 11,000 individuals in the United States.
Thelansis’s “Gorlin Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gorlin Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Gorlin Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Gorlin Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
